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OBJECTIVE — To clarify the relationship between lipid levels and ischemic heart disease
(IHD) and cerebrovascular disease (CVD) in diabetic individuals.
RESEARCHDESIGNANDMETHODS — TheJapanCholesterolandDiabetesMellitus
Study is a prospective cohort study of 4,014 type 2 diabetic patients (1,936 women; mean  SD
age 67.4  9.5 years). Lipid and glucose levels and other factors were investigated in relation to
occurrence of IHD or CVD.
RESULTS — IHD and CVD occurred in 1.59 and 1.43% of participants, respectively, over a
2-year period. The relation of lower HDL or higher LDL cholesterol to occurrence of IHD in
subjects 65 years old was signiﬁcant. Lower HDL cholesterol was also signiﬁcantly related to
CVD in subjects 65 years old and especially in those 75 years old (n  1,016; odds ratio
0.511 [95% CI 0.239–0.918]; P  0.05). Stepwise multiple regression analysis with onset of
CVD as a dependent variable showed the same result.
CONCLUSIONS — Lower HDL cholesterol is an important risk factor for not only IHD but
also CVD, especially in diabetic elderly individuals.
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T
ype 2 diabetes, dyslipidemia, and
aging are independent risk factors
for cardiovascular diseases. Japa-
nese individuals have lower rates of isch-
emic heart disease (IHD) and higher rates
of cerebrovascular disease (CVD); how-
ever, diabetic individuals have an in-
creased risk of IHD (1,2). Risk factors for
IHD or CVD in elderly diabetic individu-
als are not fully known (3), and the Japan
Cholesterol and Diabetes Mellitus Study
was formulated to evaluate them (Umin
Clinical Trials Registry, clinical trial reg.
no. UMIN00000516; http://www.umin.
ac.jp/ctr/index.htm).
RESEARCH DESIGN AND
METHODS— The Japan Cholesterol
and Diabetes Mellitus Study is a single-
center prospective cohort study com-
prised of 4,014 Japanese diabetic
individuals on a consecutive outpatient
basis recruited between September 2004
and March 2005 (1,936 women; mean 
SD age 67.4  9.5 years [range 35–83
years]).PatientswithpreviousIHD(myo-
cardial infarction, unstable angina pecto-
ris, angioplasty, or bypass grafting) or
CVD (stroke) were excluded. Follow-up
information was available for 98.2 and
92.3% of patients enrolled in the ﬁrst and
second years, respectively. Patients were
dividedintothoseaged65years,65–74
years, and 75 years (n  1,267, 1,731,
and 1,016, respectively). The primary
end points were onset of IHD or CVD.
Plasma lipid, glucose, A1C, and other rel-
evant levels were measured annually.
The study was approved by institu-
tional review boards and by the safety-
monitoring board. All events were
conﬁrmed by the organizing committee
annually.TheguidelinesoftheJapanAth-
erosclerosis Society (2002), stating that
LDL cholesterol should be 120 mg/dl
and HDL cholesterol 40 mg/dl in dia-
betic individuals, and the American Dia-
betes Association criteria for diagnosis of
type 2 diabetes were used (4,5).
Results are presented as means  SD.
Allstatisticalanalyseswereperformedus-
ing JMP software (SAS Institute, Cary,
NC).Incidenceswereanalyzedinrelation
toriskfactors.Univariateandmultiplelo-
gistic regression analysis and stepwise
analysis were used. Values of P  0.05
were considered signiﬁcant.
RESULTS— Mean A1C, fasting
plasma glucose, LDL cholesterol, triglyc-
eride, HDL cholesterol, and systolic and
diastolicbloodpressurelevelsonregistra-
tion were 7.53  1.12%, 159.4  52.7
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mg/dl, 55.8  18.0 mg/dl, 136.5  17.1
mmHg, and 75.1  11.1 mmHg, respec-
tively. Insulin and oral agents for diabetes
were prescribed for 19.9 and 70.5% of
individuals, respectively. Dyslipidemia
was seen in 79.1%, and antihyperlipi-
demic drugs were prescribed in 59.0%.
Mean lipid and glucose metabolism levels
did not change signiﬁcantly over the
2-year study period.
In the ﬁrst and second years, 83 and
69 vascular events occurred, respectively.
IHD and CVD occurred in 0.80 and
0.71% of total patients per year. The rela-
tionship between IHD or CVD and back-
ground factors such as LDL cholesterol
levels in each age-group was analyzed by
univariate logistic regression.
Sex, age, LDL cholesterol, HDL cho-
lesterol, and triglyceride were signiﬁ-
cantly related to IDH in patients aged
65 years. Age, sex, history of hyperten-
sion, and antihypertensive drugs were re-
lated in patients aged between 65 and 74
years, and sex and systolic and diastolic
blood pressure were related in patients
aged  75 years. CVD and LDL choles-
terol were related in patients aged 65
years, and HDL cholesterol and systolic
blood pressure were related in patients
aged 75 years.
We performed multiple regression
analysis with factors found to be signiﬁ-
cant by univariate regression analysis for
IHD or CVD and other atherogenic risk–
related factors (A1C, etc.) in three age-
groups(Table1).LDLandHDLcholesterol
were associated with IHD in patients
aged  65 years but not in other age-
groups. Sex was associated with IHD in
individuals aged 74 years. HDL choles-
terol was also associated with CVD in in-
dividuals between aged between 65 and
74 years and 75 years.
Stepwise multiple regression analysis
was performed using factors that were
found to be signiﬁcant by univariate re-
gression analysis for IHD or CVD and
other atherogenic risk–related factors.
HDLandLDLcholesterolwereassociated
with IHD in individuals aged 65 years
(HDLcholesteroloddsratio0.79[95%CI
0.58–0.96; P  0.04] and LDL choles-
terol 0.60 [0.33–0.99; P  0.04]). HDL
cholesterol was associated with CVD in
individualsagedbetween65and74years
and 75 years (65–74 years 0.73 [0.56–
0.94; P  0.04] and 75 years 0.60
[0.35–0.91; P  0.01]).
TherelationofageorHDLcholesterol
toIHDandCVDwasevaluatedinquartile
categories. HDL cholesterol levels were
inversely correlated with IHD in individ-
uals aged 65 years (hazards ratio 0.633
[95% CI 0.428–0.975]) but not in other
groups. The relationship between CVD
and HDL cholesterol was prominent in
thoseaged75yearsbutnotinotherage-
groups (Table 1). There were no sex-
related differences in the relationship of
HDL cholesterol with CVD. There was no
relationship between LDL, triglyceride,
fasting blood glucose, or A1C and the fre-
quency of CVD.
Table 1—Adjusted multiple regression analyses of factors found to be signiﬁcant by univariate regression analysis for IHD or CVD, as well as
major atherogenic risk factors; total n  4,014
65 years old (n  1,276) 65–74 years old (n  1,731) 75 years old (n  1,016)
Adjusted OR (95% CI) P Adjusted OR (95% CI) P Adjusted OR (95% CI) P
IHD
Sex 1.469 (1.02–1.94) 0.02* 1.109 (1.02–1.74) 0.04* 0.829 (0.23–3.06) 0.78
Age 1.063 (0.96–1.20) 0.28 0.991 (0.86–1.15) 0.99 0.996 (0.83–1.17) 0.87
LDL cholesterol 1.225 (1.02–2.04) 0.04* 1.001 (0.72–1.25) 0.89 0.776 (0.43–1.40) 0.40
HDL cholesterol 0.659 (0.39–0.98) 0.04* 0.939 (0.68–1.25) 0.38 0.946 (0.58–1.29) 0.23
Triglycerides 1.356 (1.00–2.02) 0.05 0.731 (0.52–1.94) 0.18 0.881 (0.46–1.70) 0.71
A1C 1.179 (0.75–1.88) 0.27 1.082 (0.76–1.55) 0.67 1.274 (0.57–2.35) 0.44
SBP 0.702 (0.49–1.09) 0.15 1.082 (0.79–1.69) 0.15 1.051 (0.58–1.89) 0.87
DBP 1.020 (0.97–1.05) 0.28 1.088 (0.73–1.27) 0.24 1.998 (0.99–4.35) 0.08
CVD
Sex 1.158 (0.68–2.17) 0.47 1.004 (0.79–1.69) 0.82 0.847 (0.45–1.52) 0.58
Age 1.006 (0.94–1.10) 0.88 0.982 (0.82–1.14) 0.39 1.139 (0.99–1.30) 0.06
LDL cholesterol 1.099 (0.98–1.23) 0.06 1.067 (0.76–1.44) 0.51 1.128 (0.64–1.59) 0.71
HDL cholesterol 0.888 (0.64–1.48) 0.09 0.758 (0.53–0.98) 0.04* 0.511 (0.24–0.92) 0.04*
Triglycerides 1.147 (0.68–2.04) 0.62 1.070 (0.69–1.67) 0.75 1.355 (0.75–2.56) 0.32
A1C 0.996 (0.64–1.28) 0.52 1.019 (0.75–1.74) 0.54 1.015 (0.60–1.72) 0.95
SBP 1.005 (0.67–1.33) 0.86 0.991 (0.94–1.13) 0.35 1.063 (0.62–1.57) 0.75
DBP 1.109 (0.61–2.13) 0.74 1.303 (0.81–2.09) 0.27 1.045 (0.68–1.5) 0.59
IHD CVD
65 years
old
65–74 years
old
75 years
old Total
65 years
old
65–74 years
old
75 years
old Total
HDL cholesterol (mg/dl)
44 2.31 2.49 1.68 2.14 1.13 1.99 2.62* 2.01
44–53 1.45 1.45 1.64 1.50 1.05 1.84 2.15* 1.64
54–63 1.25 1.41 0.98 1.23 1.44 0.80 0.88* 1.04
64 0.42 1.69 0.99 1.19 1.0 0.80 0.45* 0.72
Datawereadjustedforsex.Theratioofmaletofemalesubjectsis1:1.*Statisticallysigniﬁcant(P0.05).DBP,diastolicbloodpressure;SBP,systolicbloodpressure.
Age-based changes in risk for atherosclerotic diseases
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sents one of the largest-scale attempts to
examine IHD and CVD in middle-aged
and elderly diabetic individuals. In the
U.S., evidence suggests that middle-aged
diabeticindividualshaveanIHDrisksim-
ilar to that for individuals with myocar-
dialinfarction(6).However,thisriskmay
not exist in elderly diabetic individuals.
Many guidelines to prevent atherothrom-
botic diseases recommend strict control
ofLDLcholesterolindiabeticpatientsbut
the same guideline for HDL cholesterol
control (40 mg/dl) as that used for nondi-
abetic subjects (4–7).
A novel ﬁnding was that type 2 dia-
betic elderly individuals had frequent
CVD, and incidence rates were associated
with HDL cholesterol. Few data were
available for the relationship among el-
derly, type 2 diabetes, and CVD (8,9).
There have been three large-scale
clinical studies of statins that included
participants aged up to 75 years (10–12).
Although they reported that statins ex-
ertedeffectsonIHD(includingindiabetic
individuals), effects were not pro-
nounced. (Prosper reported that statins
induced a 16% decrease in IHD without
anyeffectsonCVD.)Thedatasuggestthat
because LDL cholesterol decreased, sim-
ple LDL cholesterol control may not pre-
vent IHD or CVD in elderly individuals.
Our study shows the importance of HDL
cholesterol in CVD in elderly diabetic in-
dividuals and in IHD in middle-aged dia-
betic individuals. If HDL cholesterol is
well controlled in elderly diabetic pa-
tients, then CVD and IHD might be de-
creasedtothelevelsfoundinmiddle-aged
cohorts.Patientsprescribedstatinswhose
HDL cholesterol was 40 mg/dl showed
the same risk (data not shown). Although
medicated patients may be more con-
scious of diseases, HDL cholesterol is a
strong risk factor and masks the effects of
statins.
In conclusion, HDL and LDL choles-
terol were risk factors for IHD in diabetic
patients aged 65 years. In addition,
HDLcholesterolwasariskfactorforCVD
in elderly diabetic subjects, especially
those aged 75 years. HDL cholesterol
may help prevent CVD in elderly diabetic
subjects. Risk factors for IHD and CVD
appear to change with advancing age.
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